This is an archive page from 2017
Dr Mallon is an Infectious Diseases Specialist at the Mater Misericordiae University Hospital, Dublin. Dr Mallon graduated in medicine from Queen’s University Belfast, Northern Ireland and underwent training in infectious diseases in Sydney, Australia, where he completed a PhD examining antiretroviral toxicities. Dr Mallon heads the HIV Molecular Research Group, which focuses on translational research into toxicities of antiretroviral therapy, including cardiovascular disease, adipose tissue toxicity and bone disease. Dr Mallon is a Regional Representative for the European AIDS Clinical Society (EACS), is Deptuy Chair of the EACS Comorbidities Guidelines Panel and is Deputy Director of the Wellcome Trust / HRB Irish Clinicial Academic Training Programme. He has published more than one hundred peer-reviewed manuscripts and sits on the editorial board of AIDS, HIV Medicine and AIDS Research and Therapy.
Peter Reiss is Professor of Medicine at the Academic Medical Center in Amsterdam, the Netherlands, where he holds a joint appointment in the Department of Global Health and the Division of Infectious Diseases.
Peter Reiss has been Director of the Netherlands HIV Monitoring Foundation since February 2013. He also serves on the Scientific Advisory Boards of the Agence Nationale de Recherches sur de Sida et les hepatitis virales (ANRS) and the Swiss HIV Cohort Study, as well as on the Steering Committees of the D:A:D study, the Antiretroviral Therapy Cohort Collaboration and the EuroSida Study. In addition, Peter Reiss is one of the four rotating scientific coordinators of EuroCoord.
Dr. Reiss is clinical HIV section editor for Antiviral Therapy and editorial board member of a number of other journals. He is also Immediate Past President of the European Aids Clinical Society (EACS) and, until 2014, served as the European and Central Asia regional representative on the Governing Council of the International Aids Society (IAS). His current research focuses primarily on the complications of HIV and HIV treatment, and more particularly in relation to ageing.
Dr. Alan Landay is Professor and Chairman of the Department of Immunology/Microbiology at Rush University Medical Center in Chicago. He has been involved in HIV research for over 35 years having performed some of the first immune evaluations of HIV infected haemophiliacs in 1982 while completing a postdoctoral fellowship at the University of Alabama, Birmingham. Dr. Landay joined the faculty at Rush University Medical Center in 1983 and helped establish the HIV research program which has grown to encompass both a basic and translational focus on immune studies in HIV. Dr. Landay served as Chair of the National Committee of Clinical Laboratory Standards Committee on Flow Cytometry which produced the first national standard on CD4 testing. He has also served as an advisor to the College of American Pathologists, NIH and WHO on standardization of CD4 Testing and serves on the Bill and Melinda Gates Foundation Global Health Care Technologies Committee. Dr. Landay’s current research focus is on immune pathogenesis and immune based therapy of HIV disease. He also studies HIV and aging and the role of the mucosal immune system and microbiome in HIV pathogenesis .He is past Chair of the Immunology Research Agenda Committee of the AIDS Clinical Trial Group NIH Program and he has served on the Executive Committee of the Forum for HIV Collaborative Research. . He also serves on the Office of AIDS Research HIV and Aging Committee. He serves on NIH, AmFar, Glazer Pediatric AIDS Foundation and State of California Grant review panels and is past Chair of the NIH HIV Vaccine Study Section. He has served as a mentor for over 15 graduate students and postdoctoral fellows who have gone on to obtain academic positions. Dr. Landay has published over 400 peer reviewed papers focused on basic and clinical studies of HIV with an emphasis on the role of immune activation inflammation and microbiome in HIV pathogenesis and therapy.
Laura Benjamin is an NIHR Clinical Lecturer in Neurology, at the Institute of Infection and Global Health, University of Liverpool. She’s currently undertaking a sub-specialty clinical training in stroke medicine at the National Hospital for Neurology and Neurosurgery, University College London Hospitals. Her research interest is in HIV infection and stroke, and she has completed a Wellcome Trust funded PhD in this area. She’s extending her remit into the mechanism and interplay of chronic viral infections (including HIV and herpesvirus infections), inflammatory mediators and cardiovascular disease outcomes, through a recently funded GSK grant.
Alan Winston is a Professor of HIV and Genitourinary Medicine at Imperial College and Consultant Physician at St. Mary’s Hospital, London. He has an MD in antiretroviral clinical pharmacology and his research focuses on non-infectious co-morbidities associated with HIV-disease in the modern antiretroviral era, with a strong focus on central nervous system complications.
Dr Alan Winston qualified from Glasgow University and undertook training in general medicine and HIV medicine in the UK and Australia. He leads the HIV and GU clinical trials unit at St. Mary’s hospital which runs over 20 studies at one time.
He is the principal clinical investigator on the POPPY study, a cohort study describing the incidence and nature of co-morbidities in HIV.
Juliet Compston OBE MD, FRCP, FRCPE, FRCPath, FMedSci is Emeritus Professor of Bone Medicine at the University of Cambridge School of Clinical Medicine. Her research is focused on the pathophysiology of osteoporosis and the cellular and structural mechanisms by which pharmacological interventions preserve bone mass and reduce fracture risk. She has conducted studies into the pathophysiology of bone disease in a number of disorders, including postmenopausal osteoporosis, post-transplantation osteoporosis and cystic fibrosis. Recently her research has focused on fractures in obese postmenopausal women.
Professor Compston is Editor-in-Chief of the Journal of Bone and Mineral Research. She is a past President of the Bone and Tooth Society of Great Britain, as well as a past Chairman and President of the International Society of Bone Morphometry. She is Chair of the European Union Osteoporosis Consultation Panel and of the UK National Osteoporosis Guidelines Group. She has published over 350 original research papers and reviews.
In 2006, Professor Compston was awarded the National Osteoporosis Society Kohn Foundation Award, and in 2009, the International Bone and Mineral Society John G Haddad Jr Award and the ASBMR Frederic C Bartter Award. In 2014 she was appointed an Officer of the Order of the British Empire for services to the treatment of osteoporosis.
Dr Aoife Cotter is currently working as a Consultant in Infectious Diseases at the Mater Misericordiae and St Vincent’s University Hospitals. She completed a PhD focussing on cohort methodology and bone disease in HIV under the supervision of Dr Paddy Mallon (HMRG/ University College Dublin) and Prof Caroline Sabin (Medical Statistics and Epidemiology, University College London). In addition to HIV UPBEAT, a longitudinal cohort exploring bone health, new research interests include exploring radiological and clinical changes in those undergoing contemporary hepatitis C treatment (The TRACER Cohort) and bone, kidney and gut microbiome alterations around antiretroviral therapy initiation (The BIGGER Study). Future, projects hope to exploit contemporary mobile health technologies to assess frailty and ultimately to promote healthy ageing in people living with HIV.
Donal O’Shea began his cardiology and endocrinology career in Hammersmith Hospital, London. On completion of his MD, Prof. O’Shea was appointed to Consultant Physician and Senior Lecturer in Diabetes and Endocrinology at Hammersmith Hospital. He returned to Ireland and set up the first hospital-based multidisciplinary treatment unit for obesity in Ireland before going on to become a member of the Department of Health National Obesity Taskforce, chairing the detection and treatment subgroup. Prof. O’Shea is currently Consultant in Endocrinology and Diabetes at St Columcille’s and St Vincent’s University Hospitals, Dublin, and is Chairman of the Nutrition Council of the Irish Heart Foundation, representing Ireland on the UK and Ireland Neuroendocrine Tumour Network. He has also published on diabetes, obesity, gender identity disorder, steroid metabolism, gut endocrine tumours and thyroid disorders.
Prof. Georg MN Behrens is Professor for T Cell Immunology in the Department for Clinical Immunology and Rheumatology and Head of the DFG-funded Clinical Research Group KFO 250 at Hannover Medical School, Hannover Germany.
He is an internationally acknowledged expert on HIV-therapy and related metabolic side effects and has received several awards for his research in this area. In addition, his lab works on antigen presentation by dendritic cells (e.g. cross-presentation), anti-viral immunity and autoimmunity in transgenic mouse models. He has published numerous papers in journals such as Lancet, J Exp Med, J Clin Invest, Nat Immunol, AIDS, J Immunol and others. His laboratory is supported by the German Research Foundation (KFO 250, SFB 900, SFB 578), the Federal Ministry of Education and Research and others. He is principal investigator of national and international studies in HIV medicine and member of European Collaborations such as NEAT and HIVERA Network.
He is president of the German AIDS Society, a Co-chair of the panel for the European Guidelines on prevention and management of non-infectious co-morbidities in HIV, a member of the Excellence Cluster »REBIRTH – From Regenerative Biology to Reconstructive Therapy«, and a faculty member of the Hannover Biomedical Research School (HBRS). He is reviewer for international journals in immunology and infectious diseases and is in the Editorial Boards of AIDS, Antiviral Therapy, HIV Medicine and Experimental Biology and Medicine.
This meeting is supported by educational grants from ViiV Healthcare, Gilead Sciences, Merck Sharp & Dohme and Janssen Sciences Ireland which have taken no role in designing the agenda or educational content of the meeting